id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2026-P-0749-0001,FDA,FDA-2026-P-0749,Citizen Petition from Apotex Inc.,Other,Citizen Petition,2026-01-26,2026,1,2026-01-26,2026-07-23,2026-01-27 01:08:18,,1,0,09000064b9182c73
FDA-2026-D-1255-0002,FDA,FDA-2026-D-1255,Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing; Draft Guidance for Industry,Other,Guidance,2026-04-15,2026,4,2026-04-15,2026-07-15,2026-04-16 09:00:16,,1,0,09000064b9282a2a
FDA-2025-D-2837-0002,FDA,FDA-2025-D-2837,Questions and Answers About Requirements for Additional Traceability Records for Certain Foods: Guidance for Industry - Draft Guidance,Other,Guidance,2026-02-20,2026,2,2026-02-20,2026-05-22,2026-02-20 20:47:16,,1,0,09000064b91c9d9a
FDA-2026-N-1304-0001,FDA,FDA-2026-N-1304,Agenda for the U.S. Food and Drug Administration (FDA) Virtual Public Meeting Food Allergen Thresholds and Their Potential Applications 2-18-2026,Other,Agenda,2026-02-18,2026,2,2026-02-18,2026-05-20,2026-04-10 09:00:23,,1,0,09000064b91b5eeb
FDA-2025-D-6131-0002,FDA,FDA-2025-D-6131,General Considerations for the Use of New Approach Methodologies in Drug Development; Guidance for Industry - Draft Guidance,Other,Guidance,2026-03-19,2026,3,2026-03-19,2026-05-19,2026-04-15 09:00:24,,1,0,09000064b9223609
FDA-2026-D-1817-0002,FDA,FDA-2026-D-1817,Flavored Electronic Nicotine Delivery Systems (ENDS) Premarket Applications—Considerations Related to Youth Risk - Draft Guidance for Industry,Other,Guidance,2026-03-11,2026,3,2026-03-11,2026-05-12,2026-04-14 09:00:19,,1,0,09000064b920c96d
FDA-2011-D-0611-0094,FDA,FDA-2011-D-0611,"New and Revised Draft Q&As on Biosimilar Development and the BPCI Act (Revision 4) Guidance for Industry - 
Draft Guidance",Other,Guidance,2026-03-10,2026,3,2026-03-10,2026-05-12,2026-03-14 09:00:14,,1,0,09000064b92071bb
FDA-2025-D-1504-0002,FDA,FDA-2025-D-1504,Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection: Draft Guidance for Industry,Other,Guidance,2026-03-09,2026,3,2026-03-09,2026-05-09,2026-04-10 09:00:26,,1,0,09000064b9200f6d
FDA-2024-D-4388-0002,FDA,FDA-2024-D-4388,New Clinical Investigation Exclusivity (3-Year Exclusivity) for Drug Products: Questions and Answers Guidance for Industry - Draft Guidance,Other,Guidance,2026-03-04,2026,3,2026-03-04,2026-05-05,2026-03-09 09:00:19,,1,0,09000064b91ef6ec
FDA-2007-D-0369-2444,FDA,FDA-2007-D-0369,PSG_020151 - Draft Guidance on Venlafaxine Hydrochloride,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:22:37,,1,0,09000064b91df4e6
FDA-2007-D-0369-2442,FDA,FDA-2007-D-0369,PSG_020144 - Draft Guidance on Nitroglycerin,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:21:57,,1,0,09000064b91df4d8
FDA-2007-D-0369-2432,FDA,FDA-2007-D-0369,PSG_018084 - Draft Guidance on Tolmetin Sodium,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:18:51,,1,0,09000064b91df465
FDA-2007-D-0369-2457,FDA,FDA-2007-D-0369,PSG_021336 - Draft Guidance on Selegiline,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:26:39,,1,0,09000064b91e011b
FDA-2007-D-0369-2440,FDA,FDA-2007-D-0369,PSG_019982 - Draft Guidance on Bisoprolol Fumarate,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:21:21,,1,0,09000064b91df4d4
FDA-2007-D-0369-2447,FDA,FDA-2007-D-0369,PSG_020375 - Draft Guidance on Estradiol,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:23:38,,1,0,09000064b91df4f2
FDA-2007-D-0369-2438,FDA,FDA-2007-D-0369,PSG_019813 - Draft Guidance on Fentanyl,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:20:47,,1,0,09000064b91df4d0
FDA-2007-D-0369-2459,FDA,FDA-2007-D-0369,PSG_021427 - Draft Guidance on Duloxetine Hydrochloride,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:27:37,,1,0,09000064b91e011f
FDA-2007-D-0369-2461,FDA,FDA-2007-D-0369,PSG_021514 - Draft Guidance on Methylphenidate,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:29:28,,1,0,09000064b91e0123
FDA-2007-D-0369-2520,FDA,FDA-2007-D-0369,PSG_218466 - Draft Guidance on Alpelisib,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:50:12,,1,0,09000064b91e01d3
FDA-2007-D-0369-2511,FDA,FDA-2007-D-0369,PSG_216352 - Draft Guidance on Paliperidone Palmitate,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:47:03,,1,0,09000064b91e01b4
FDA-2007-D-0369-2512,FDA,FDA-2007-D-0369,PSG_216665 - Draft Guidance on Diazoxide Choline,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:47:20,,1,0,09000064b91e01b6
FDA-2007-D-0369-2508,FDA,FDA-2007-D-0369,PSG_215431 - Draft Guidance on Meloxicam; Rizatriptan Benzoate,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:46:07,,1,0,09000064b91e01ad
FDA-2007-D-0369-2475,FDA,FDA-2007-D-0369,PSG_202211 - Draft Guidance on Oxybutynin,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:35:11,,1,0,09000064b91e0140
FDA-2007-D-0369-2466,FDA,FDA-2007-D-0369,PSG_022029 - Draft Guidance on Menthol; Methyl Salicylate,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:31:54,,1,0,09000064b91e012d
FDA-2007-D-0369-2467,FDA,FDA-2007-D-0369,PSG_022083 - Draft Guidance on Rivastigmine,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:32:28,,1,0,09000064b91e012f
FDA-2007-D-0369-2464,FDA,FDA-2007-D-0369,PSG_021829 - Draft Guidance on Rotigotine,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:30:54,,1,0,09000064b91e0129
FDA-2007-D-0369-2497,FDA,FDA-2007-D-0369,PSG_213224 - Draft Guidance on Octreotide acetate,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:42:17,,1,0,09000064b91e018a
FDA-2007-D-0369-2490,FDA,FDA-2007-D-0369,PSG_211843 - Draft Guidance on Tiopronin,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:39:55,,1,0,09000064b91e0172
FDA-2007-D-0369-2481,FDA,FDA-2007-D-0369,PSG_207620 - Draft Guidance on Sacubitril; Valsartan,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:37:17,,1,0,09000064b91e0156
FDA-2007-D-0369-2489,FDA,FDA-2007-D-0369,PSG_211733 - Draft Guidance on Acetaminophen; Ibuprofen,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:39:39,,1,0,09000064b91e0170
FDA-2007-D-0369-2479,FDA,FDA-2007-D-0369,PSG_206089 - Draft Guidance on Testosterone Undecanoate,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:36:31,,1,0,09000064b91e0152
FDA-2007-D-0369-2469,FDA,FDA-2007-D-0369,PSG_022264 - Draft Guidance on Paliperidone Palmitate,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:33:09,,1,0,09000064b91e0133
FDA-2007-D-0369-2473,FDA,FDA-2007-D-0369,PSG_085635 - Draft Guidance on Testosterone Cypionate,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:34:27,,1,0,09000064b91e013c
FDA-2007-D-0369-2488,FDA,FDA-2007-D-0369,PSG_210868 - Draft Guidance on Lorlatinib,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:39:21,,1,0,09000064b91e016e
FDA-2007-D-0369-2486,FDA,FDA-2007-D-0369,PSG_209310 - Draft Guidance on Mometasone Furoate,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:38:46,,1,0,09000064b91e016a
FDA-2007-D-0369-2506,FDA,FDA-2007-D-0369,PSG_215401 - Draft Guidance on Dextroamphetamine,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:45:23,,1,0,09000064b91e01a9
FDA-2007-D-0369-2522,FDA,FDA-2007-D-0369,PSG_218585 - Draft Guidance on Aceclidine Hydrochloride,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:51:02,,1,0,09000064b91e01d7
FDA-2007-D-0369-2509,FDA,FDA-2007-D-0369,PSG_215602 - Draft Guidance on Baclofen,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:46:21,,1,0,09000064b91e01af
FDA-2007-D-0369-2516,FDA,FDA-2007-D-0369,PSG_217225 - Draft Guidance on Avacincaptad Pegol Sodium,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:48:56,,1,0,09000064b91e01cb
FDA-2007-D-0369-2507,FDA,FDA-2007-D-0369,PSG_215429 - Draft Guidance on Venlafaxine Besylate,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:45:49,,1,0,09000064b91e01ab
FDA-2007-D-0369-2443,FDA,FDA-2007-D-0369,PSG_020145 - Draft Guidance on Nitroglycerin,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:22:16,,1,0,09000064b91df4da
FDA-2007-D-0369-2460,FDA,FDA-2007-D-0369,PSG_021447 - Draft Guidance on Tizanidine Hydrochloride,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:27:59,,1,0,09000064b91e0121
FDA-2007-D-0369-2446,FDA,FDA-2007-D-0369,PSG_020357 - Draft Guidance on Metformin Hydrochloride,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:23:14,,1,0,09000064b91df4f0
FDA-2007-D-0369-2448,FDA,FDA-2007-D-0369,PSG_020489 - Draft Guidance on Testosterone,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:23:57,,1,0,09000064b91df4f4
FDA-2007-D-0369-2454,FDA,FDA-2007-D-0369,PSG_021234 - Draft Guidance on Diclofenac Epolamine,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:25:35,,1,0,09000064b91e010a
FDA-2007-D-0369-2500,FDA,FDA-2007-D-0369,PSG_214410 - Draft Guidance on Baloxavir Marboxil,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:43:31,,1,0,09000064b91e0190
FDA-2007-D-0369-2494,FDA,FDA-2007-D-0369,PSG_212516 - Draft Guidance on Duloxetine Hydrochloride,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:41:20,,1,0,09000064b91e0184
FDA-2007-D-0369-2484,FDA,FDA-2007-D-0369,PSG_208143 - Draft Guidance on Barium Sulfate,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:38:13,,1,0,09000064b91e015c
FDA-2007-D-0369-2495,FDA,FDA-2007-D-0369,PSG_212526 - Draft Guidance on Alpelisib,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:41:39,,1,0,09000064b91e0186
FDA-2007-D-0369-2476,FDA,FDA-2007-D-0369,PSG_203479 - Draft Guidance on Clozapine,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:35:30,,1,0,09000064b91e014c
FDA-2007-D-0369-2482,FDA,FDA-2007-D-0369,PSG_207962 - Draft Guidance on Lidocaine,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:37:34,,1,0,09000064b91e0158
FDA-2007-D-0369-2480,FDA,FDA-2007-D-0369,PSG_206968 - Draft Guidance on Acetaminophen,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:36:59,,1,0,09000064b91e0154
FDA-2007-D-0369-2429,FDA,FDA-2007-D-0369,PSG_012283 - Draft Guidance on Chlorthalidone,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:17:46,,1,0,09000064b91df45f
FDA-2007-D-0369-2441,FDA,FDA-2007-D-0369,PSG_020076 - Draft Guidance on Nicotine,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:21:38,,1,0,09000064b91df4d6
FDA-2007-D-0369-2435,FDA,FDA-2007-D-0369,PSG_018891 - Draft Guidance on Clonidine,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:19:51,,1,0,09000064b91df4ca
FDA-2007-D-0369-2453,FDA,FDA-2007-D-0369,PSG_021180 - Draft Guidance on Ethinyl Estradiol; Norelgestromin,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:25:18,,1,0,09000064b91e0108
FDA-2007-D-0369-2439,FDA,FDA-2007-D-0369,PSG_019927 - Draft Guidance on Ketoconazole,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:21:03,,1,0,09000064b91df4d2
FDA-2007-D-0369-2523,FDA,FDA-2007-D-0369,PSG_219016 - Draft Guidance on Rilpivirine Hydrochloride,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:51:25,,1,0,09000064b91e01d9
FDA-2007-D-0369-2514,FDA,FDA-2007-D-0369,PSG_216962 - Draft Guidance on Foscarbidopa; Foslevodopa,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:48:20,,1,0,09000064b91e01ba
FDA-2007-D-0369-2517,FDA,FDA-2007-D-0369,PSG_217370 - Draft Guidance on Acoltremon,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:49:14,,1,0,09000064b91e01cd
FDA-2007-D-0369-2515,FDA,FDA-2007-D-0369,PSG_217202 - Draft Guidance on Landiolol Hydrochloride,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:48:39,,1,0,09000064b91e01bc
FDA-2007-D-0369-2492,FDA,FDA-2007-D-0369,PSG_212304 - Draft Guidance on Donepezil Hydrochloride,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:40:33,,1,0,09000064b91e0180
FDA-2007-D-0369-2503,FDA,FDA-2007-D-0369,PSG_215039 - Draft Guidance on Alpelisib,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:44:36,,1,0,09000064b91e0196
FDA-2007-D-0369-2493,FDA,FDA-2007-D-0369,PSG_212306 - Draft Guidance on Selinexor,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:40:55,,1,0,09000064b91e0182
FDA-2007-D-0369-2498,FDA,FDA-2007-D-0369,PSG_213953 - Draft Guidance on Testosterone Undecanoate,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:42:31,,1,0,09000064b91e018c
FDA-2007-D-0369-2472,FDA,FDA-2007-D-0369,PSG_050440 - Draft Guidance on Cephalexin,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:34:04,,1,0,09000064b91e013a
FDA-2007-D-0369-2485,FDA,FDA-2007-D-0369,PSG_208171 - Draft Guidance on Ferric Derisomaltose,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:38:28,,1,0,09000064b91e015e
FDA-2007-D-0369-2501,FDA,FDA-2007-D-0369,PSG_214522 - Draft Guidance on Tadalafil,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:44:01,,1,0,09000064b91e0192
FDA-2007-D-0369-2491,FDA,FDA-2007-D-0369,PSG_212268 - Draft Guidance on Asenapine,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:40:16,,1,0,09000064b91e017e
FDA-2007-D-0369-2477,FDA,FDA-2007-D-0369,PSG_204017 - Draft Guidance on Ethinyl Estradiol; Levonorgestrel,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:35:51,,1,0,09000064b91e014e
FDA-2007-D-0369-2496,FDA,FDA-2007-D-0369,PSG_213004 - Draft Guidance on Amoxicillin; Omeprazole Magnesium; Rifabutin,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:41:55,,1,0,09000064b91e0188
FDA-2007-D-0369-2434,FDA,FDA-2007-D-0369,PSG_018859 - Draft Guidance on Ribavirin,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:19:33,,1,0,09000064b91df4c8
FDA-2007-D-0369-2431,FDA,FDA-2007-D-0369,PSG_017874 - Draft Guidance on Scopolamine,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:18:30,,1,0,09000064b91df463
FDA-2007-D-0369-2449,FDA,FDA-2007-D-0369,PSG_020538 - Draft Guidance on Estradiol,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:24:10,,1,0,09000064b91df4f6
FDA-2007-D-0369-2462,FDA,FDA-2007-D-0369,PSG_021588 - Draft Guidance on Imatinib Mesylate,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:29:47,,1,0,09000064b91e0125
FDA-2007-D-0369-2513,FDA,FDA-2007-D-0369,PSG_216675 - Draft Guidance on Perfluorohexyloctane,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:47:39,,1,0,09000064b91e01b8
FDA-2007-D-0369-2510,FDA,FDA-2007-D-0369,PSG_216318 - Draft Guidance on Testosterone Cypionate,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:46:43,,1,0,09000064b91e01b1
FDA-2007-D-0369-2458,FDA,FDA-2007-D-0369,PSG_021351 - Draft Guidance on Oxybutynin,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:27:00,,1,0,09000064b91e011d
FDA-2007-D-0369-2456,FDA,FDA-2007-D-0369,PSG_021306 - Draft Guidance on Buprenorphine,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:26:18,,1,0,09000064b91e0119
FDA-2007-D-0369-2505,FDA,FDA-2007-D-0369,PSG_215352 - Draft Guidance on Phenylephrine Hydrochloride; Tropicamide,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-03-27 09:00:14,,1,0,09000064b91e019a
FDA-2007-D-0369-2436,FDA,FDA-2007-D-0369,PSG_019081 - Draft Guidance on Estradiol,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:20:10,,1,0,09000064b91df4cc
FDA-2007-D-0369-2455,FDA,FDA-2007-D-0369,PSG_021258 - Draft Guidance on Estradiol; Levonorgestrel,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:25:50,,1,0,09000064b91e010c
FDA-2007-D-0369-2451,FDA,FDA-2007-D-0369,PSG_020831 - Draft Guidance on Formoterol Fumarate,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:24:44,,1,0,09000064b91e0104
FDA-2007-D-0369-2450,FDA,FDA-2007-D-0369,PSG_020612 - Draft Guidance on Lidocaine,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:24:27,,1,0,09000064b91df4f8
FDA-2007-D-0369-2430,FDA,FDA-2007-D-0369,PSG_017628 - Draft Guidance on Tolmetin Sodium,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:18:11,,1,0,09000064b91df461
FDA-2007-D-0369-2465,FDA,FDA-2007-D-0369,PSG_021986 - Draft Guidance on Dasatinib,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:31:13,,1,0,09000064b91e012b
FDA-2007-D-0369-2483,FDA,FDA-2007-D-0369,PSG_208036 - Draft Guidance on Barium Sulfate,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:37:51,,1,0,09000064b91e015a
FDA-2007-D-0369-2468,FDA,FDA-2007-D-0369,PSG_022198 - Draft Guidance on Granisetron,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:32:47,,1,0,09000064b91e0131
FDA-2007-D-0369-2470,FDA,FDA-2007-D-0369,PSG_022395 - Draft Guidance on Capsaicin,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:33:25,,1,0,09000064b91e0135
FDA-2007-D-0369-2518,FDA,FDA-2007-D-0369,PSG_217514 - Draft Guidance on Dabrafenib Mesylate,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:49:32,,1,0,09000064b91e01cf
FDA-2007-D-0369-2478,FDA,FDA-2007-D-0369,PSG_205395 - Draft Guidance on Cobicistat; Darunavir Ethanolate,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:36:14,,1,0,09000064b91e0150
FDA-2007-D-0369-2487,FDA,FDA-2007-D-0369,PSG_210136 - Draft Guidance on Buprenorphine,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:39:03,,1,0,09000064b91e016c
FDA-2007-D-0369-2502,FDA,FDA-2007-D-0369,PSG_214826 - Draft Guidance on Lorazepam,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:44:20,,1,0,09000064b91e0194
FDA-2007-D-0369-2504,FDA,FDA-2007-D-0369,PSG_215110 - Draft Guidance on Glecaprevir; Pibrentasvir,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:44:51,,1,0,09000064b91e0198
FDA-2007-D-0369-2474,FDA,FDA-2007-D-0369,PSG_202155 - Draft Guidance on Apixaban,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:34:51,,1,0,09000064b91e013e
FDA-2007-D-0369-2499,FDA,FDA-2007-D-0369,PSG_214187 - Draft Guidance on Sofosbuvir; Velpatasvir,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:43:04,,1,0,09000064b91e018e
FDA-2007-D-0369-2471,FDA,FDA-2007-D-0369,PSG_022549 - Draft Guidance on Loxapine,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:33:45,,1,0,09000064b91e0138
FDA-2007-D-0369-2463,FDA,FDA-2007-D-0369,PSG_021590 - Draft Guidance on Clozapine,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:30:34,,1,0,09000064b91e0127
FDA-2007-D-0369-2452,FDA,FDA-2007-D-0369,PSG_020870 - Draft Guidance on Estradiol; Norethindrone Acetate,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:25:03,,1,0,09000064b91e0106
FDA-2007-D-0369-2445,FDA,FDA-2007-D-0369,PSG_020310 - Draft Guidance on Ketoconazole,Other,Guidance,2026-02-27,2026,2,2026-02-27,2026-04-29,2026-02-27 19:22:59,,1,0,09000064b91df4ee